Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network

Kevin Winthrop, S. Yamashita, S. E. Beekmann, P. M. Polgreen

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

Original languageEnglish (US)
Pages (from-to)1738-1740
Number of pages3
JournalClinical Infectious Diseases
Volume46
Issue number11
DOIs
StatePublished - Jun 1 2008

Fingerprint

Biological Therapy
Tumor Necrosis Factor-alpha
Infection
Histoplasmosis
Consultants
Communicable Diseases
Staphylococcus aureus
Tuberculosis
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

@article{3031421f7b024be5a0931802b3a7afed,
title = "Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network",
abstract = "We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.",
author = "Kevin Winthrop and S. Yamashita and Beekmann, {S. E.} and Polgreen, {P. M.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1086/587989",
language = "English (US)",
volume = "46",
pages = "1738--1740",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies

T2 - Case finding through the emerging infections network

AU - Winthrop, Kevin

AU - Yamashita, S.

AU - Beekmann, S. E.

AU - Polgreen, P. M.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

AB - We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

UR - http://www.scopus.com/inward/record.url?scp=43949117120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949117120&partnerID=8YFLogxK

U2 - 10.1086/587989

DO - 10.1086/587989

M3 - Article

C2 - 18419421

AN - SCOPUS:43949117120

VL - 46

SP - 1738

EP - 1740

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -